PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL- A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2373
https://www.valueinhealthjournal.com/article/S1098-3015(18)35675-4/fulltext
Title :
PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL- A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35675-4&doi=10.1016/j.jval.2018.09.2373
First page :
Section Title :
Open access? :
No
Section Order :
1736